Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Pan Z, et al. Among authors: young pr. ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221. ChemMedChem. 2007. PMID: 17154430 No abstract available.
Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo.
Spencer JR, Sendzik M, Oeh J, Sabbatini P, Dalrymple SA, Magill C, Kim HM, Zhang P, Squires N, Moss KG, Sukbuntherng J, Graupe D, Eksterowicz J, Young PR, Myers AG, Green MJ. Spencer JR, et al. Among authors: young pr. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4884-8. doi: 10.1016/j.bmcl.2006.06.085. Epub 2006 Jul 25. Bioorg Med Chem Lett. 2006. PMID: 16870445
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
Baker B, Bermingham IM, Leelasena I, Hickling J, Young PR, Muller DA, Forster AH. Baker B, et al. Among authors: young pr. Vaccines (Basel). 2023 Nov 17;11(11):1725. doi: 10.3390/vaccines11111725. Vaccines (Basel). 2023. PMID: 38006057 Free PMC article.
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, Liang B, Li Z, Wijesundara DK, Lackenby JA, Griffin P, Bennet JK, Hensen L, Zhang W, Nguyen THO, Tran MH, Tapley P, Barnes J, Reading PC, Kedzierska K, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP. Chappell KJ, et al. Among authors: young pr. EBioMedicine. 2023 Nov;97:104842. doi: 10.1016/j.ebiom.2023.104842. Epub 2023 Oct 20. EBioMedicine. 2023. PMID: 37865043 Free PMC article. Clinical Trial.
408 results